3D bioprinting market size to grow by USD 2,015.81M from 2022-27

The 3D bioprinting market size is estimated to grow by USD 2,015.81 million from 2022 to 2027, growing at a CAGR of 19.94%. North America is estimated to account for 31% of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. In 2022, North America accounted for the largest revenue share of the global 3D bioprinting market. In North America, the US and Canada are the significant revenue contributors to the market in focus. Moreover, the growth of the market in focus in the region can be attributed to enhanced healthcare infrastructure, high adoption of 3D bioprinting technologies in healthcare facilities, and the presence of established companies.

Key developments:

• Rapid advances in technology, intense competition, and changing dynamics in the market are the key factors for the intense competition among vendors.
• With the rising competition, the market will see consolidation. However, manufacturing complexities and high production costs pose significant risk factors for vendors in the market.

Major drivers & challenges
The advancements in 3D bioprinting technology are notably driving the 3D bioprinting market growth. The 3D bioprinting market is being significantly fueled by the continued progress in 3D bioprinting technologies, such as better bio-ink formulations, printing methods, and tissue engineering strategies. Such advancements permit the creation of more complex and functional tissue structures, which will change the field of regeneration medicine. The new formulations of bio-inks enhance cell survival, promote tissue fusion and make it more comfortable to construct structures that are personalized for each patient. Moreover, advancements in printing methods, including the use of multiple printheads or extruders, enable the simultaneous deposition of several cell types and materials, delivering more accurate and intricate tissue constructs. Moreover, creative approaches to tissue engineering, e.g., bioprinting on pre-pasteurized substrates or the application of thin fibrin networks, deliver exciting options for building strong and efficient tissues. Thus, the emergence of 3D bioprint technology is boosting market growth and driving boundaries for regenerative medicine and personalized health care by improving the likelihood that tissues or organs will be developed in accordance with both physiological and therapeutic needs. Therefore, such factors are expected to drive market growth during the forecast period.

The inability of researchers to combine vascular supply in printed tissues and organs is a major challenge impeding market growth. Despite significant advancements in the 3D bioprinting market, the complete bioprinting of fully functional organs or tissues for transplant remains a challenge. While researchers have successfully bioprinted parts of organs or tissues with functional cells, integrating vascular veins within the printed organs remains a hurdle. Though vascular veins can be printed separately, the bioprinted product requires a vascular system and proper blood flow for optimal functionality. The current limitations on vascular integration restrict the thickness and viability of the printed tissue. Until a viable and fully intact organ is developed for transplantation, the growth of the 3D bioprinting market may be constrained. Commercial availability of this technology to end users is not anticipated in the foreseeable future, making the challenge of integrating blood vessel supply a potential hindrance to the market’s growth over the forecast period.

Key trends
The fabrication of complex tissues is an emerging trend shaping market growth. A significant trend in the global 3D bioprinting market is the focus on fabricating complex tissues and multi-organ complexes. Researchers are exploring the simultaneous printing of various cell types, extracellular matrix, and growth hormones to create functioning tissues with intricate structures. The development of such multi-organ complexes and complex tissues has promising implications for personalized healthcare and regenerative medicine. As a result, this trend is expected to strongly influence the market’s growth over the forecast period. Technavio